Clolar Related Published Studies
Well-designed clinical trials related to Clolar (Clofarabine)
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. [2008.09.01]
Other research related to Clolar (Clofarabine)
Clofarabine in refractory Langerhans cell histiocytosis. [2008.11]
Clofarabine combinations as acute myeloid leukemia salvage therapy. [2008.10.15]
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as frontline therapy for patients age >= 60 years with acute myeloid leukemia and high-risk myelodysplastic syndrome. [2008.06.18]
The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report. [2008]
Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine. [2007.12]
Clofarabine: past, present, and future. [2007.10]
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. [2007.09.15]
Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia. [2007.09]
A phase I clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. [2007.06.11]
Clofarabine for the treatment of acute lymphoblastic leukemia. [2007.02]
Nursing considerations for clofarabine in the treatment of acute lymphoblastic leukemia in children. [2006.12]
Discovery and development of clofarabine: a nucleoside analogue for treating cancer. [2006.10]
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. [2006.07.01]
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. [2006.04.20]
Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. [2005.12]
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. [2005.05.15]
Clofarabine. [2005.05]
Biochemical modulation of cytarabine triphosphate by clofarabine. [2005.04]
Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia. [2005.03]
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. [2005.02.01]
Clofarabine: in pediatric patients with acute lymphoblastic leukemia. [2005]
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. [2004.11]
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. [2004.10]
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. [2004.02.01]
Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. [2003.12.15]
Induction of complete remission using single agent clofarabine in a patient with primary refractory acute myeloblaste leukemia. [2003.12]
Clofarabine. Bioenvision/ILEX. [2003.12]
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. [2003.10.01]
Clofarabine-induced acral erythema during the treatment of patients with myelodysplasia and acute leukemia: report of two cases. [2003.08]
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. [2003.03.15]
Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. [2003.03]
Other possibly related research studies
New nucleoside analogs in the treatment of solid tumors. [2004.07]
New nucleoside analogs in the treatment of hematological disorders. [2004.05]
New designs for phase 2 clinical trials. [2003.07.15]
Hematologic malignancies: new developments and future treatments. [2002.08]
New drugs in acute myeloid leukemia. [2002.09]
Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. [2000.11.15]
Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. [1999]
Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine in rats. [1994]
Gateways to clinical trials. [2006.11]
Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. [2006]
Gateways to clinical trials. [2006.10]
Pharmacological and clinical studies on purine nucleoside analogs--new anticancer agents. [2006.05]
Treatment of older patients with acute myeloid leukemia--new agents. [2006.04]
New agents for the treatment of acute myeloid leukemia. [2006]
Gateways to clinical trials. [2005.09]
New agents in the treatment of childhood leukemias and myelodysplastic syndromes. [2005.11]
Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. [2005.09]
Gateways to clinical trials. [2005.06]
Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. [2004.12]
Gateways to clinical trials. [2004.07]
Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. [2004.08]
Purine nucleoside antimetabolites in development for the treatment of cancer. [2004.06]
Gateways to clinical trials. [2004.01]
Gateways to clinical trials. [2003.12]
Gateways to clinical trials. [2003.11]
Gateways to clinical trials. [2003.07]
Advanced-phase chronic myeloid leukemia. [2003.01]
Nucleoside analogues in the treatment of haematological malignancies. [2001.06]
New directions in the treatment of mantle cell lymphoma: an overview. [2006.10]
Saccharomyces cerevisiae emboli in an immunocompromised patient with relapsed acute myeloid leukaemia. [2007.07]
Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. [2007.12]
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. [2008.03]
Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy. [2008]
New drugs in acute myeloid leukemia. [2008.08]
Acute myeloid leukemia in the elderly. [2008.08]
Novel purine nucleoside analogues for hematological malignancies. [2008.06]
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. [2008.07]
|
